Resistance to BRAF-targeted therapy in melanoma

BRAF mutations are identified in 40–50% of patients with melanoma. Treatment of these patients with either of two BRAF inhibitors (vemurafenib, dabrafenib) or the MEK inhibitor trametinib is associated with improved clinical benefit (response rate, progression free survival, and overall survival) co...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	European journal of cancer (1990) Ročník 49; číslo 6; s. 1297 - 1304
Hlavní autori:	Sullivan, Ryan J., Flaherty, Keith T.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Kidlington Elsevier Ltd 01.04.2013 Elsevier
Predmet:	Biological and medical sciences BRAF inhibitor resistance Disease-Free Survival Drug Resistance, Neoplasm - genetics Hematology, Oncology and Palliative Medicine Humans Imidazoles - therapeutic use Indoles - therapeutic use MAP Kinase Signaling System - drug effects Medical sciences Melanoma Melanoma - drug therapy Melanoma - genetics Molecular targeted therapy Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Mutation Oximes - therapeutic use Pharmacology. Drug treatments Protein Kinase Inhibitors - therapeutic use Proto-Oncogene Proteins B-raf - antagonists & inhibitors Proto-Oncogene Proteins B-raf - genetics Pyridones - therapeutic use Pyrimidinones - therapeutic use Sulfonamides - therapeutic use Tumors Molecular targeted therapy BRAF inhibitor resistance Melanoma Targeted therapy Malignant tumor Resistance BRAF Gene Cancerology Treatment C-Onc gene Targeted drug Malignant melanoma Inhibitor Protooncogene Cancer
ISSN:	0959-8049, 1879-0852, 1879-0852
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!